BioVex Inc has raised $40 million to fund the Phase III trial of its melanoma cancer vaccine after seeing an "unprecedented number of durable complete remissions" in Phase II, and is working to raise another $20 million to prepare for a filing in 2010. That is the sixth round of private funding from investors who have patiently supported the company since it was spun out of University College London in 1999. BioVex moved its headquarters to Woburn, Mass, in 2005 to enable it to tap U.S. markets, but failed to get enough interest reran initial public offering in 2006. The company's R&D remains at the former headquarters in …
No comments:
Post a Comment